Literature DB >> 23846405

Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire.

William Ngo1, Ping Situ, Nancy Keir, Donald Korb, Caroline Blackie, Trefford Simpson.   

Abstract

PURPOSE: To characterize the psychometric properties of the standard patient evaluation of eye dryness (SPEED) questionnaire and to validate and compare its performance with 4 existing dry eye questionnaires.
METHODS: A total of 50 subjects (40 female and 10 male) were enrolled; of these, 30 were symptomatic and 20 asymptomatic, as determined using the ocular surface disease index (OSDI). This study consisted of 2 visits in which all subjects completed 5 different dry eye questionnaires (SPEED, OSDI, dry eye questionnaire, McMonnies dry eye questionnaire, and subjective evaluation of symptom of dryness) in random order at each visit. Clinical measurements were obtained on the first visit. Repeatability was determined using concordance correlation coefficient; dimensionality was determined using principal component, factor, and Rasch analyses; and validity was determined by comparing SPEED scores with dry eye diagnosis based on OSDI (primarily using receiver-operator curve analysis).
RESULTS: The SPEED questionnaire data were found to be unidimensional and repeatable. Three principal components (dryness, burning, and soreness/fatigue) were identified and SPEED between visit concordance correlation coefficient was 0.923 (95% confidence interval, 0.868-0.955). The area under the receiver-operator curves was 0.928. The only clinical measures that correlated "well" with SPEED questionnaire scores were corneal staining (P < 0.05), meibomian gland score (P < 0.05), and meibomian glands yielding liquid secretion score (P < 0.05).
CONCLUSIONS: The SPEED questionnaire was shown to be a repeatable and valid instrument for measurement of dry eye symptoms. The SPEED score also correlated significantly with ocular surface staining and clinical measures of meibomian gland function.

Entities:  

Mesh:

Year:  2013        PMID: 23846405     DOI: 10.1097/ICO.0b013e318294b0c0

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  70 in total

Review 1.  TFOS DEWS II pain and sensation report.

Authors:  Carlos Belmonte; Jason J Nichols; Stephanie M Cox; James A Brock; Carolyn G Begley; David A Bereiter; Darlene A Dartt; Anat Galor; Pedram Hamrah; Jason J Ivanusic; Deborah S Jacobs; Nancy A McNamara; Mark I Rosenblatt; Fiona Stapleton; James S Wolffsohn
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

Review 2.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.

Authors:  Mark S Milner; Kenneth A Beckman; Jodi I Luchs; Quentin B Allen; Richard M Awdeh; John Berdahl; Thomas S Boland; Carlos Buznego; Joseph P Gira; Damien F Goldberg; David Goldman; Raj K Goyal; Mitchell A Jackson; James Katz; Terry Kim; Parag A Majmudar; Ranjan P Malhotra; Marguerite B McDonald; Rajesh K Rajpal; Tal Raviv; Sheri Rowen; Neda Shamie; Jonathan D Solomon; Karl Stonecipher; Shachar Tauber; William Trattler; Keith A Walter; George O Waring; Robert J Weinstock; William F Wiley; Elizabeth Yeu
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

3.  Validity and Reliability of a Novel Ocular Pain Assessment Survey (OPAS) in Quantifying and Monitoring Corneal and Ocular Surface Pain.

Authors:  Yureeda Qazi; Shelley Hurwitz; Sarosh Khan; Ula V Jurkunas; Reza Dana; Pedram Hamrah
Journal:  Ophthalmology       Date:  2016-04-16       Impact factor: 12.079

4.  In vivo detection of clinically non-apparent ocular surface inflammation in patients with meibomian gland dysfunction-associated refractory dry eye symptoms: a pilot study.

Authors:  Y Qazi; A Kheirkhah; C Blackie; A Cruzat; M Trinidad; C Williams; D R Korb; P Hamrah
Journal:  Eye (Lond)       Date:  2015-06-19       Impact factor: 3.775

Review 5.  Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zachariah DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Igor Petriček
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

Review 6.  Understanding Neuropathic Corneal Pain--Gaps and Current Therapeutic Approaches.

Authors:  Sunali Goyal; Pedram Hamrah
Journal:  Semin Ophthalmol       Date:  2016       Impact factor: 1.975

7.  [Comparison of the OSDI and SPEED questionnaires for the evaluation of dry eye disease in clinical routine].

Authors:  D Finis; N Pischel; C König; J Hayajneh; M Borrelli; S Schrader; G Geerling
Journal:  Ophthalmologe       Date:  2014-11       Impact factor: 1.059

8.  Short-Term Changes in Tear Lipid Layer Thickness After Instillation of Lipid Containing Eye Drops.

Authors:  Phoebe Lim; Tun Aung Han; Louis Tong
Journal:  Transl Vis Sci Technol       Date:  2020-07-17       Impact factor: 3.283

Review 9.  Neuropathic Corneal Pain: Approaches for Management.

Authors:  Gabriela Dieckmann; Sunali Goyal; Pedram Hamrah
Journal:  Ophthalmology       Date:  2017-11       Impact factor: 12.079

10.  Meibomian gland dropout in Sjögren's syndrome and non-Sjögren's dry eye patients.

Authors:  Siwen Zang; Ying Cui; Yang Cui; Wenlei Fei
Journal:  Eye (Lond)       Date:  2018-06-22       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.